Navigation Links
NORTHWEST BIO Announces Positive Third Quarter Progress
Date:10/6/2011

BETHESDA, Md., Oct. 6, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it has exceeded its Q3 projection of 15 clinical trial sites by the end of the quarter, with 17 sites at major medical institutions across the U.S. now open and active where patients can enroll in the Company's ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.  The Company likewise exceeded its Q2 projections, as previously announced.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company said it is continuing to add clinical trial sites in the U.S. and Europe.  The Company expects to have 25 sites open and active by the end of the next quarter (Q4), with further growth expected into 2012.  Open and active trial sites are listed on the U.S. Government's website, www.clinicaltrials.gov, and on NORTHWEST BIO's website www.nwbio.com  

The Company's clinical trial site expansion reflects growing interest from both physicians and patients, and a growing awareness of the positive data from the Company's prior clinical trials for GBM brain cancer.  In those trials, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who receive standard of care (surgery, radiation and chemotherapy).  Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care.  DCVax® was well-tolerated, with no toxic side effects.

NORTHWEST BIO's current clinical trial for GBM brain cancer also offers a key difference from other immune therapy trials currently under way. &#
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
2. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
3. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Northwest Biotherapeutics Announces Change and Expansion of Management Team
6. Northwest Biotherapeutics Announces Series of Financing Arrangements
7. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Northwest Biotherapeutics Addresses Recent Market Activity
10. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
11. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Inc. (Nasdaq: CALP ) today announced that ... will be webcast on Thursday,January 10, 2008 at ... of,Caliper, will be providing an update on the ... http://www.metameetings.com/webcasts/jpmorgan/healthcare08/ . An archived,presentation will be available for ...
... Md., Jan. 3 EntreMed, Inc.,(Nasdaq: ... for the treatment of cancer and inflammatory ... Drug Administration (FDA) has accepted its,Investigational New ... ENMD-2076., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ...
... Sweden, January 3 Amic AB (Uppsala, Sweden),announced ... license under,patent rights of Roche Diagnostics to commercialise ... market., NT-proBNP is a key cardiac marker ... diagnosis and management of heart failure, and,risk stratification ...
Cached Biology Technology:EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 2EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 3
(Date:10/22/2014)... Oct. 20, 2014  Leading identity analyst firm Acuity ... of the world,s population will have a chip-based National ... Europe . Asia , with ... accounting for more than 60% of all National eID ... report  -- "The Global National eID Industry ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... PHILADELPHIA Molecular biologist Jonathan Brody, Ph.D., ... Goney, Ph.D., research assistant professor, and member of ... in the Department of Pathology, Anatomy and Cell ... University have been awarded a W.W. Smith Charitable ...
... an important breakthrough, scientists at McMaster University have discovered how ... The discovery, published in the prestigious science journal Nature ... needing blood for surgery, cancer treatment or treatment of other ... created from a patch of their own skin to provide ...
... Philadelphia, Pa. Examining the blood "metabolomics" ... cigarette revealed activation of pathways involved in cell ... say researchers at Georgetown Lombardi Comprehensive Cancer Center, ... They say their findings, presented at the Ninth ...
Cached Biology News:Jefferson researchers receive W.W. Smith Charitable Trust 2Jefferson researchers receive W.W. Smith Charitable Trust 3Studying the metabolome of smokers, Lombardi researchers find early signs of damage 2
Protein Marker Detection Pack contains biotinylate...
JMJD2B Antibody...
Agarose, Biotechnology grade, 500g...
... proto-oncogene was first identified as the cellular homolog ... B and Jun D have been shown to ... regions, which are involved in dimerization and DNA ... in transcriptional activation, diverge. Antigen: ...
Biology Products: